Empirical therapy of febrile neutropenic patients with mucositis: challenge of risk-based therapy  N.M.A. Blijlevens, J.P. Donnelly, B.E. de Pauw  Clinical Microbiology and Infection  Volume 7, Pages 47-52 (January 2001) DOI: 10.1046/j.1469-0691.2001.00058.x Copyright © 2001 European Society of Clinical Infectious Diseases Terms and Conditions

Fig. 1 Least-squares regression curves of the daily mucositis score and granulocytes of 28 allogenic hematopoietic stem cell transplant recipients who had received idarubicin, cyclophosphamide and total body irradiation as conditioning therapy. The course of oral mucositis parallels that of neutropenia [1 8]. Clinical Microbiology and Infection 2001 7, 47-52DOI: (10.1046/j.1469-0691.2001.00058.x) Copyright © 2001 European Society of Clinical Infectious Diseases Terms and Conditions

Fig. 2 Algorithm for the management of the febrile neutropenic patient with mucositis. Patients who have developed mucositis following treatment with high-dose cytarabine, idarubicin or cyclophosphamide are considered to be at a high risk of developing bacteremia. This will be known within 72 h of starting empirical monotherapy, allowing other drugs to be added as and when necessary. Clinical Microbiology and Infection 2001 7, 47-52DOI: (10.1046/j.1469-0691.2001.00058.x) Copyright © 2001 European Society of Clinical Infectious Diseases Terms and Conditions